Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate

Allarity Therapeutics (NASDAQ: ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 97.54 percent increase over losses of $(7.71) per share from the same period last year.